osteoclast

(redirected from Osteoclasts)
Also found in: Thesaurus, Medical, Encyclopedia.

os·te·o·clast

 (ŏs′tē-ə-klăst′)
n.
1. A large multinucleate cell found in growing bone that resorbs bony tissue, as in the formation of canals and cavities.
2. An instrument used in surgical osteoclasis.

[osteo- + Medieval Latin -clastēs, breaker (from Late Greek -klastēs, from Greek klastos, broken, from klān, to break).]

os′te·o·clas′tic adj.

osteoclast

(ˈɒstɪəʊˌklæst)
n
1. (Surgery) a surgical instrument for fracturing bone
2. (Physiology) a large multinuclear cell formed in bone marrow that is associated with the normal absorption of bone
ˌosteoˈclastic adj

os•te•o•clast

(ˈɒs ti əˌklæst)

n.
1. a skeletal cell that functions in bone formation.
2. a surgical instrument for effecting osteoclasis.
[1870–75; osteo- + -clast < Greek klastós broken]
os`te•o•clas′tic, adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.osteoclast - cell that functions in the breakdown and resorption of bone tissue
bone cell - a cell that is part of a bone
Translations
Osteoklast
luunsyöjäsolu

os·te·o·clast

n. osteoclasto, célula gigante multinucleada que participa en la formación de tejido óseo y reemplaza al cartílago durante la osificación.
References in periodicals archive ?
XGEVA is the first fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL) a protein essential for the formation, function and survival of osteoclasts, cells which break down bone thereby inhibiting osteoclast-mediated bone destruction.
It is a fully human monoclonal antibody that binds to and neutralises RANK ligand (RANKL), a protein essential for the formation, function and survival of osteoclasts, which break down bone, thereby inhibiting osteoclast-mediated bone destruction.
XGEVA is a fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL)--a protein essential for the formation, function and survival of osteoclasts, which break down bone--thereby inhibiting osteoclast-mediated bone destruction.
Background: Osteoclasts are multinucleated bone-resorbing cells that differentiate in response to receptor activator of nuclear factor-[kappa]-B (NF-[kappa]B) ligand (RANKL).
The 2 main types of bone cells are osteoblasts and osteoclasts (1).
Serial transverse sections of each maxilla in the interradicular bone at furcation area of first molar distobuccal root of control and appliance side were obtained for quantification of osteoclasts by histomorphometric study.
The characteristic feature of malignant infantile osteopetrosis (MIOP), an autosomal recessive disorder, is the decreased activity of osteoclasts leading to generalized bone osteosclerosis.
Several studies have proved that strontium can stimulate the calcium-sensing receptor, CaSR, situated in the membrane of osteoblasts and osteoclasts (16).
Two key cells are involved in the turnover of bone in adults: osteoclasts and osteoblasts.
Forteo stimulates both bone formation and bone loss, but has a positive net effect, and Prolia strongly inhibits osteoclasts.
The RANKL binds directly with RANK which are present on preosteoclasts and increases differentiation of osteoclast progenitors and mature osteoclasts.
Recently, research has shown that the process of vascular calcification resembles the process of bone formation, involving bone forming cells, osteoblasts, and bone absorbing cells, osteoclasts.